Filter
Exclude
Time range
-
Near
Evangelos Triantafyllou@TriantafyllouE_
25 Mar 2022
Congrats Dr Gudd (@CathrinLC)🍾making us proud againπŸ₯²Poster winner | BSI #CheckpointBlockade2022
BSI Tumour Immunology@BSI_TumourImm
25 Mar 2022
Congrats to our poster winners @CathrinLC, Chun Wai Wong and Martin Fellermeyer! Our poster prize was kindly sponsored by proteomic innovators IsoPlexis! Check out what they do here πŸ‘‰ isoplexis.com/ @bsicongress @britsocimm #CheckpointBlockade2022 #TIG22
12
BSI Tumour Immunology@BSI_TumourImm
25 Mar 2022
Congrats to our poster winners @CathrinLC, Chun Wai Wong and Martin Fellermeyer! Our poster prize was kindly sponsored by proteomic innovators IsoPlexis! Check out what they do here πŸ‘‰ isoplexis.com/ @bsicongress @britsocimm #CheckpointBlockade2022 #TIG22
3
19
BSI Tumour Immunology@BSI_TumourImm
24 Mar 2022
Thank you to everyone who came along and participated in #CheckpointBlockade2022 yesterday!! πŸ˜ƒ We hope you enjoyed the event! Please remember to complete the feedback forms and if you want to get in touch drop us a Tweet or send us an email! πŸ˜ƒ βœ‰οΈtinyurl.com/2yjddxaw
8
F-star, an invoX Company@Fstar_Inc
23 Mar 2022
Great event today with @BSI_TumourImm We presented posters on two of our tetravalent #bispecific antibodies, FS120 and FS222. #checkpointblockade2022 f-star.com/pipeline/ #immunooncology
Rafaella Giambalvo, scientist at F-star Therapeutics presented a poster on FS120, an OX40/CD137 tetravalent bispecific dual agonist antibody, synergistically increases the anti-tumor activity of anti-PD-1 in preclinical studies at the BSI Tumour Immunology Affinity Group meeting. Jennifer Ofoedu also of F-star Therapeutics, presented on FS222, a tetravalent bispecific antibody targeting CD137 and PD-L1, designed for optimal CD137 interactions resulting in potent T cell activation without toxicity.

ALT Rafaella Giambalvo, scientist at F-star Therapeutics presented a poster on FS120, an OX40/CD137 tetravalent bispecific dual agonist antibody, synergistically increases the anti-tumor activity of anti-PD-1 in preclinical studies at the BSI Tumour Immunology Affinity Group meeting. Jennifer Ofoedu also of F-star Therapeutics, presented on FS222, a tetravalent bispecific antibody targeting CD137 and PD-L1, designed for optimal CD137 interactions resulting in potent T cell activation without toxicity.

3
Immunotherapy Advances Journal@IMTadvances
23 Mar 2022
πŸ“£ Share your insights on the latest #immunotherapy clinical trials in your specialism! Our #TrialsWatch series includes this excellent article from Prof Gary Middleton @BSI_TumourImm ⭐ Learn more about the series & contribute: bit.ly/ITATrialsWatch #CheckpointBlockade2022
1
2
2
Immunotherapy Advances Journal@IMTadvances
23 Mar 2022
Calling @BSI_TumourImm #CheckpointBlockade2022 attendees! We've launched a #CallForPapers for our new Special Collection 'Adoptive cellular #immunotherapies' led by Prof @TaoDong14 ✨ Head to bit.ly/ITAcelltherapy to find out more & submit your #CellTherapy research!
1
3
9
BSI Tumour Immunology@BSI_TumourImm
23 Mar 2022
Prof Gary Middleton kicking off our first in person meeting!! A great and enthusiastic overview! πŸ‘ @bsicongress @britsocimm #CheckpointBlockade2022 #TIG22
1
8
Immunotherapy Advances Journal@IMTadvances
23 Mar 2022
Attending #CheckpointBlockade2022 & looking to publish your next paper? We're a fully #OpenAccess journal from @britsocimm spanning the translational pipeline for #immunotherapy research 🎯 BSI members get discounted #OA fees! Explore our scope: bit.ly/3irD3Vd
1
3
BSI Tumour Immunology@BSI_TumourImm
21 Mar 2022
Blimey!! 🚨 Only two days to go until our #CheckpointBlockade2022 event!! 🚨 Still got a few tickets left, check out our line-up and register here πŸ‘‰ bit.ly/3BlUL5e How is everyone getting to #Birmingham? Public transport I hope, gotta save the planet! #TIG22
2
7
BSI Congress & Events@bsicongress
18 Mar 2022
πŸ‘€ Great thread below from @PanettiSilvia exploring the programme of @BSI_TumourImm's inaugural meeting #CheckpointBlockade2022 taking place this Wednesday 23 March in Birmingham! There's still time to register πŸ‘‰bit.ly/3BlUL5e

SilviaPanetti@PanettiSilvia
17 Mar 2022
When planning the launch event of the @BSI_TumourImm group, our aim was to bring together brains from different paths of #cancerimmunotherapy This is what we came up with –> tinyurl.com/36w9sukp Explore with us what reshaped the filed –#Chekpointblockade πŸ”₯ 🧡 1/14
2
3
BSI Tumour Immunology@BSI_TumourImm
16 Mar 2022
Only one week to go!! 🚨🚨 Are you ready? Our last speaker is oncology clinical trials guru Prof Gary Middleton who will explore targeting #TIGIT! A few tickets left πŸ‘‰tinyurl.com/36w9sukp @CIIC_UoB @ImmunologyUoB @IcgsUob #TIG22 #CheckpointBlockade2022
3
4
BSI Congress & Events@bsicongress
16 Mar 2022
Have you seen the programme for #CheckpointBlockade2022? ✨ Our @BSI_TumourImm have put together an amazing lineup of speakers: πŸ”Ή Dr Shoba Amarnath πŸ”Ή Prof Jannie Borst πŸ”Ή Prof Simon Davis πŸ”Ή Dr Ping-Chih Ho πŸ”Ή Dr Kevin Litchfield 1/2
1
2
3
BSI Tumour Immunology@BSI_TumourImm
14 Mar 2022
Next week Matilde Saggese, Vice President Medical Director at @achillestx, will discuss a vision of patient-specific therapeutics and potential combinations with checkpoint inhibitors. πŸ‘‰ tinyurl.com/36w9sukp @bsicongress @TheCrick #CheckpointBlockade2022 #TIG22
2
4
BSI Tumour Immunology@BSI_TumourImm
3 Mar 2022
Lots of exciting talks lined up for our meeting! We are looking forward to hearing from Dr Shoba Amarnath from @UniofNewcastle on the regulation of ILCs by PD-1! πŸ‘‰ tinyurl.com/36w9sukp @NCL_medresearch @nubiosciences @LEOFondet @bsicongress #CheckpointBlockade2022 #TIG22
3
11
BSI Tumour Immunology@BSI_TumourImm
2 Mar 2022
🚨 Last chance to apply for a BSI Travel or Carers' Grant for our #CheckpointBlockade2022 conference!! Deadline is today!! 🚨 #TIG22 Travel grant πŸ‘‰tinyurl.com/2ndphjhh Carer's grant πŸ‘‰tinyurl.com/yckfj5bx Event registration πŸ‘‰tinyurl.com/36w9sukp @bsicongress
1
1
BSI Congress & Events@bsicongress
1 Mar 2022
Last chance to apply for @britsocimm Regional & Affinity Group grants to support your attendance at @BSI_TumourImm #CheckpointBlockade2022! Travel & carer's grant applications close tomorrow (2 March) ⏰ BSI members, apply now πŸ‘‰bit.ly/3pcLqHL
1
1
BSI Tumour Immunology@BSI_TumourImm
18 Feb 2022
🚨 Today is Abstract Deadline Day!! Which is a lot like Transfer Deadline Day⚽️, except MORE exciting! 🚨 Be a part of our #CheckpointBlockade2022 meeting and showcase your work! Abstracts hereπŸ‘‰tinyurl.com/h86vtn5k Register hereπŸ‘‰tinyurl.com/36w9sukp #DeadlineDay #TIG22

Abstract Submission: Checkpoint blockade – understanding mechanisms, unlocking new approaches

Abstract submission form for poster presentation at Checkpoint blockade – understanding mechanisms, unlocking new approaches to be held on Wednesday 23 March 2022 at the IET Birmingham: Austin Court,...

docs.google.com
BSI Congress & Events@bsicongress
18 Feb 2022
🚨 Last chance to submit your abstract for #CheckpointBlockade2022 🚨 Don't miss out on the chance to be part of @BSI_TumourImm's inaugural meeting bringing together #cancer #immunotherapy experts from around the UK! Abstract submission closes TODAY ➑bit.ly/3BlUL5e
2
3
BSI Congress & Events@bsicongress
18 Feb 2022
🚨 Last chance to submit your abstract for #CheckpointBlockade2022 🚨 Don't miss out on the chance to be part of @BSI_TumourImm's inaugural meeting bringing together #cancer #immunotherapy experts from around the UK! Abstract submission closes TODAY ➑bit.ly/3BlUL5e
2
3
BSI Congress & Events@bsicongress
14 Feb 2022
Abstract submission for @BSI_TumourImm's #CheckpointBlockade2022 closes this Friday 18 Feb πŸ”” Submit your abstract now to present your work at this meeting which brings together basic scientists, #translational clinicians & industry partners πŸ”¬πŸ₯ΌπŸ’Ό πŸ”—bit.ly/3BlUL5e
7
7
BSI Congress & Events@bsicongress
7 Feb 2022
πŸ’₯ Abstract deadline Friday 18 Feb πŸ’₯ 'Checkpoint blockade – understanding mechanisms, unlocking new approaches' will take place on 23 March in Birmingham & is organised by our @BSI_TumourImm Submit your abstract today πŸ‘‰buff.ly/3yIJWZy #CheckpointBlockade2022
3
3
Load more